Catalyst Biosciences, Inc. (CBIO) Sees Unusually-High Trading Volume
Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) saw unusually-strong trading volume on Wednesday . Approximately 8,714,744 shares changed hands during trading, an increase of 5,876% from the previous session’s volume of 145,834 shares.The stock last traded at $3.78 and had previously closed at $3.39.
A number of equities research analysts have recently issued reports on CBIO shares. Chardan Capital started coverage on shares of Catalyst Biosciences in a research report on Monday, June 12th. They set a “buy” rating and a $10.00 price objective for the company. Ladenburg Thalmann Financial Services started coverage on shares of Catalyst Biosciences in a research report on Tuesday, June 6th. They set a “buy” rating and a $11.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, June 5th.
The stock’s 50 day moving average price is $3.66 and its 200 day moving average price is $4.88. The firm’s market capitalization is $15.21 million.
Catalyst Biosciences (NASDAQ:CBIO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.46) by $1.07. Catalyst Biosciences had a negative return on equity of 92.61% and a negative net margin of 3,127.92%. The business had revenue of $0.11 million for the quarter. On average, analysts forecast that Catalyst Biosciences, Inc. will post ($7.08) earnings per share for the current year.
Institutional investors have recently modified their holdings of the stock. Virtu KCG Holdings LLC purchased a new position in shares of Catalyst Biosciences during the second quarter worth $103,000. Bank of New York Mellon Corp acquired a new stake in Catalyst Biosciences during the second quarter valued at $107,000. Zacks Investment Management acquired a new stake in Catalyst Biosciences during the second quarter valued at $147,000. Vanguard Group Inc. grew its position in Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 32,621 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in Catalyst Biosciences during the second quarter valued at $372,000. 29.21% of the stock is owned by hedge funds and other institutional investors.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.